Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodora Bejan-Angoulvant

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
European Journal of Preventive Cardiology|May 4, 2026
Potassium on the Spot: interpreting cardiovascular risk in CKDTheodora Bejan-Angoulvant
Therapie|August 29, 2016
False positive results in preclinical researchDenis Angoulvant, Theodora Bejan-Angoulvant
Medecine Sciences : M/S|January 7, 2020
[Mechanism of action and adverse effects of monoclonal antibodies]Theodora Bejan-Angoulvant, Joachim Alexandre
Archives of Cardiovascular Diseases|October 28, 2018
The best in coronary artery disease management is yet to comeDenis Angoulvant, Theodora Bejan-Angoulvant
Presse Medicale (Paris, France : 1983)|November 17, 2019
[Endogenous and exogenous estrogens]Theodora Bejan-Angoulvant, Jean-Francois Arnal
Revue Medicale Suisse|May 24, 2011
[The problem of blood pressure targets]Rémy Boussageon, Theodora Bejan-Angoulvant, François Gueyffier
Heart (British Cardiac Society)|April 5, 2015
Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decisionDenis Angoulvant, Theodora Bejan Angoulvant, Laurent Fauchier
European Journal of Preventive Cardiology|May 7, 2026
Fibrosis and hypertension: association but not causationTheodora Bejan-Angoulvant, Jean-Baptiste de Freminville
La Revue Du Praticien|April 3, 2020
[Prescription of fixed dose combinations of antihypertensive drugs]Stéphane Laurent, Theodora Bejan-Angoulvant, Pierre Boutouyrie
European Journal of Preventive Cardiology|April 15, 2025
SGLT2 inhibitors: towards a personalized prescriptionJean-Baptiste de Freminville, Theodora Bejan-Angoulvant
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
European Journal of Preventive Cardiology|May 4, 2026
Potassium on the Spot: interpreting cardiovascular risk in CKDTheodora Bejan-Angoulvant
Therapie|August 29, 2016
False positive results in preclinical researchDenis Angoulvant, Theodora Bejan-Angoulvant
Medecine Sciences : M/S|January 7, 2020
[Mechanism of action and adverse effects of monoclonal antibodies]Theodora Bejan-Angoulvant, Joachim Alexandre
Archives of Cardiovascular Diseases|October 28, 2018
The best in coronary artery disease management is yet to comeDenis Angoulvant, Theodora Bejan-Angoulvant
Presse Medicale (Paris, France : 1983)|November 17, 2019
[Endogenous and exogenous estrogens]Theodora Bejan-Angoulvant, Jean-Francois Arnal
Revue Medicale Suisse|May 24, 2011
[The problem of blood pressure targets]Rémy Boussageon, Theodora Bejan-Angoulvant, François Gueyffier
Heart (British Cardiac Society)|April 5, 2015
Dual antiplatelet therapy after acute coronary syndrome: a cardiologist-based optimal decisionDenis Angoulvant, Theodora Bejan Angoulvant, Laurent Fauchier
European Journal of Preventive Cardiology|May 7, 2026
Fibrosis and hypertension: association but not causationTheodora Bejan-Angoulvant, Jean-Baptiste de Freminville
La Revue Du Praticien|April 3, 2020
[Prescription of fixed dose combinations of antihypertensive drugs]Stéphane Laurent, Theodora Bejan-Angoulvant, Pierre Boutouyrie
European Journal of Preventive Cardiology|April 15, 2025
SGLT2 inhibitors: towards a personalized prescriptionJean-Baptiste de Freminville, Theodora Bejan-Angoulvant
Pageof 8